highly significantp < 0.001
As shown in Figure 5 B, VP-AsA treatment significantly inhibited POD activity, particularly during early storage (days 6 and 9), where the difference from CK was highly significant ( p < 0.001). 3.5.
As shown in Figure 5 B, VP-AsA treatment significantly inhibited POD activity, particularly during early storage (days 6 and 9), where the difference from CK was highly significant ( p < 0.001). 3.5.